RE:RE:From Promis's Facebook page a few days ago
Ok, here's your blindspot RC: Promis shareholders are asked to believe and bet on very rare targets, orders of magnitude more rare than what Aducanumab, Donanemab, Lecanemab etc. target, and yet we were simultuanously asked to believe that Aducanumab would still offer just enough efficacy at sub-toxic concentrations to get some low-bar FDA approval for being first in class. It was a goldilocks argument contrived because Gene and Elliot could not find enough new shareholders.
Just how rare the targets are for PMN310 has never been spelled out, but the theory holds that the competition isn't highly selective for the right oligomer, isn't then selecting for only the particular misfolded version which self propagates to become toxic, and isn't even capable of selecting by conformational epitope expressed only on the particular misfold.
So Best in Class not First in Class (don't be first, be better, etc)= Goldilocks, and comes with the baggage of class. But it means Promis is defined by the mediocrity of the competition combined with success of regulatory capture, not unlike our legislatures. Has it worked?